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For the first time, blood samples were collected in all athletes participating in a major
sporting event of the International Association of Athletics Federations (IAAF) (Athlet-
ics World Championships 2011, Daegu, Korea). All variables obtained from blood
analyses were incorporated into the individual blood profiles of each athlete for the
so‐called athlete biological passport (ABP). This unprecedented data collection
highlighted differences for a few blood biomarkers commonly measured and reported
for the ABP on some group of athletes. Subsequently, blood tests analyses for all ath-
letes were repeated during the following World Championships (2013, Moscow, Rus-
sia). Both sets of blood tests were then used to set up the distribution of blood values
for track and field athletes considering potential confounding factors such as gender,
age, discipline, origin of the athlete (continental classification), and time of blood col-
lection. Implementation of well‐defined distribution of blood values will allow to
improve the estimation of blood doping prevalence among a specific population of
athletes in track and field.
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Throughout the years, top‐level athletes have repeatedly tried to
increase their endurance capacity and performance through erythropoi-
etin stimulating agents (ESAs) or the abuse of homologous/autologous
blood transfusion. All these substances or methods were indicated in
the prohibited list of the World Anti‐Doping Agency (WADA) in force
at the time of Track and Field World Championships in 2011 and
2013.1 ESAs and homologous blood transfusions are currently detect-
able by direct anti‐doping routine tests conducted either in urine
and/or blood2,3 while autologous blood transfusion cannot be
detected by traditional direct methods. Indirect markers are thus used
in an individual and longitudinal perspective to target and eventually
sanction athletes based on significant abnormalities observed in the
sequence of biomarkers of erythropoiesis.4,5 The determinant bio-
markers were the hemoglobin concentration, the reticulocyte count,wileyonlinelibrary.com/jourthe OFF‐score (also called stimulation index,6) and the Abnormal Blood
Profile Score (ABPS).7 The longitudinal follow‐up of these blood
parameters over time is the basic principle of the hematological mod-
ule of the so‐called athlete biological passport (ABP).7,8 The ABP
focuses on abnormal individual changes of blood biomarkers using a
Bayesian statistical approach.8,9 If an athlete has never been tested
in the past, then the initial limits are fixed by population‐based limits.
Then, each subsequent test adapts to individual limits from the initial
population limits. Consequently, inter‐subject variance is reduced,
and the specificity of the tool is significantly increased. Initial
population‐based limits were set up according to the fundamental con-
tribution of several earlier‐published scientific papers.6,10 Since then,
some pre‐analytical and analytical changes have occurred mainly
because of the establishment of specific technical documents detailing
the procedures for blood sample collection, transport, and analysis as
described in the appropriate operating WADA guidelines or technical© 2018 John Wiley & Sons, Ltd.nal/dta 1
2 ROBINSON ET AL.documents.11 The latter allowed to decrease significantly the within‐
subject variance due to a decrease of some components of the allow-
able total errors. As a consequence, the population reference values
may no longer be adapted to the current ABP12 and require a signifi-
cant update. The ABP was officially validated and launched by WADA
in 2008. The International Cycling Union (UCI) was the first interna-
tional federation to implement the ABP with the clear intention to fight
even more efficiently against blood doping. Athletes demonstrated
very atypical profiles and were finally sanctioned.13 Consequently, ath-
letes supposedly adapted their practices since blood profiles gradually
returned toward values expected from a normal population. Neverthe-
less, the ABP has been established as a deterrent tool in the fight
against blood doping.14,15
One year later, the hematological passport was implemented by
the International Association of Athletic Federation (IAAF) and quite
a few abnormal blood data were observed as in cycling. However,
some publications raised doubts on the capacity of the ABP to detect
micro ESA injections and/or regular small amounts of blood transfu-
sion.16,17 To improve the actual ABP, there is a need to investigate
whether the current distribution of blood values are still fit for pur-
pose. Another question is whether the sensitivity of the model could
be improved by replacing the universal within‐subject variance by
the implementation of an individual within‐subject variance.18
The aim of the present study is to evaluate the data from two
major events and to publish reference ranges in top‐level track and
field athletes for biomarkers of altered erythropoiesis following the
prevailing ABP guidelines.112 | SUBJECTS AND METHODS
In 2011 and 2013, all athletes taking part to IAAF World Champion-
ships in Daegu (Republic of Korea) and Moscow (Russia) underwent
blood withdrawal to supplement the individual hematological pass-
port. Reference ranges in top‐level track and field athletes were
determined for biomarkers of altered erythropoiesis considering var-
ious heterogeneous factors such as gender, age, endurance (all disci-
plines with distances ≥800 meters) or non‐endurance (all disciplines
other than endurance) disciplines, detailed sport's disciplines, the ori-
gin of the athletes, and finally the time of blood sampling. Athletes
were incorporated into six different groups of disciplines according
to WADA's specification, namely (a) sprint (100 m to 400 m events),
(b) combined events (heptathlon and decathlon), (c) jumps (long, tri-
ple, high jumps and pole vault), (d) middle distance (from 800 m to
1500 m), (e) long distance (from 3000 m to 50 km), and (f) throws
(shot put, discus throw, hammer throw, and javelin throw). The origin
of the athletes was determined following the IAAF countries' classifi-
cation made of six different continents (North America (North
America, Central America and Caribbean), South America, Africa,
Europe, Asia, and Oceania). Athletes were arranged in three different
age (A) groups (A < 20; 20 ≤ A ≤ 30; A > 30) and finally, testing
period was categorized into three separate periods (Morning
≤11:59; 12:00 ≤ Afternoon ≤16:59; Evening ≥17:00). In total,
3683 athletes from six sports disciplines (2015 male and 1668
female) were tested; they were aged between 16 and 47 years (meanage for total population was 26.0 ± 4.3 years) and originated from
173 different countries. Blood sampling took place between 07:05
and 24:00.
Upon their arrival at the competition sites, athletes were invited to
join the designated blood‐collection stations at any time of the day, at
least 24 hours after their arrival in either Daegu or Moscow, to recover
from their journey (hydration status, jetlag…). All blood tests were con-
ducted before the competition following rigorously the WADA ABP
operating guidelines11 including a questionnaire specifically designed
for the program. After blood collection, all tubes were deposited
carefully in temperature‐monitored refrigerators (for temporary
storage) and transported daily under refrigerated conditions to the
analytical facilities. The transport was done in an insulated cool box
under refrigerated conditions and temperature was recorded by a
temperature data logger as defined by the WADA standards for
testing. Blood samples were all analyzed within less than 24 hours
after withdrawal. All details of the blood collection and transport
procedures were published elsewhere.19 If an athlete was tested
more than once during an event, only the first blood test was
evaluated in this study.
Due to the high number of blood samples, each blood analytical
facility was equipped with two identical hematological analyzers, the
Sysmex XT‐2000i (Sysmex Europe, Norderstedt, Germany). In Daegu,
blood analyses were conducted by a mobile unit of the WADA‐
accredited laboratory of Lausanne whereas in Moscow, the analyses
were conducted by the local WADA‐accredited laboratory. All ana-
lyzers were carefully calibrated by the local Sysmex distributors, and
internal quality controls (E‐Checks, Level 1, 2, and 3) were run twice
before and after each batch of samples. External quality controls pro-
vided by the Quality Control Center Switzerland (CSCQ) were also
measured to assess whether instruments bias and precision were
within WADA's acceptance criteria. As required by WADA's technical
document and explained in detailed elsewhere,20 each blood sample
was analyzed twice and hemoglobin and reticulocyte count duplicates
had to be within a very narrow range. Only the first valid test results
were reported.
Samples were randomly assigned to one of the instruments at the
time of their delivery to the blood analytical facilities to avoid any mis-
interpretation due to a possible instrument bias.
For various logistical and ethical reasons, it was not possible to
record the ethnic origin of each athlete. Therefore, the indexed origin
was the country which the athlete represented in the event (also
called the sport's nationality). This nationality was then sorted based
on IAAF appropriate continental classification.
Athletes were asked to report whether they had used hypoxia
simulation devices and/or resided or trained at altitude (> 1500
meters) during the previous two weeks. Unfortunately, this
information was difficult to control without knowing the exact
whereabouts of each athlete. This was not systematically reported
by the athletes at the time of blood sampling in the Anti‐Doping
Administration and Management System (ADAMS). ADAMS is a
web‐based database management system used by WADA to manage
whereabouts information and coordinate the testing activities of the
anti‐doping organizations. Consequently, this information was not
integrated into the evaluation.
ROBINSON ET AL. 3Both blood sample collection missions were carried out under the
supervision of the personnel from IAAF's Medical & Anti‐Doping
Department whereas blood analyses were done under the supervision
of personal from the Swiss Laboratory for Doping Analyses.3 | STATISTICAL ANALYSIS
Data analysis was conducted using the R software (R Core Team
(2017)). R: A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria), version 3.3.
Before analysis, the data were cleaned, and quality controls were per-
formed. Briefly, data were checked for consistency, and every time
duplicate measurements were available, they were compared to ensure
that the difference was within acceptable range (data not shown). The
random distribution of samples over the two machines was assessed
using both graphical and statistical tools, and showed no bias linked
to gender, year of birth, continent of origin, discipline, endurance vs
non‐endurance, or time of the day (data not shown).
Values for the ABPS were calculated using a custom‐made R
package described elsewhere.7 Briefly, the ABPS combines seven
hematological markers [reticulocytes percent (RET%), hemoglobin
level (HGB), hematocrit level (HCT), red blood cell count (RBC), mean
corpuscular volume (MCV), mean corpuscular hemoglobin (MCH),
and mean corpuscular hemoglobin concentration (MCHC)] into a sin-
gle score.
An arbitrary reference population was set up; it consisted of male
European athletes, aged between 20 and 30 years old, tested in the
morning and competing in sprint discipline in Daegu (40 subjects
belonged to this reference population; this population was mainly
selected because the prevalence of blood doping was considered
low and the number of subjects was elevated). From this reference
population, adjustment values were calculated for each variable using
linear models. In this way, the model explains the observed result
according to a series of categorical variables based on gender, age,
continent of origin, discipline or “endurance”, and the competition.
When “endurance” is included in the model instead of the detailed dis-
ciplines, the reference value corresponds to an athlete competing in a
non‐endurance discipline. When necessary, the measurements were
transformed as described later.
For each parameter, two main models were considered: One with-
out any interaction between the variables, and another one where the
effect of each variable was considered differently between men and
women (with the inclusion of the interactions of all factors with the
gender variable into the model). After adjustment of all values using
the model with interactions, a normal distribution was fitted to the
data, to estimate some quantiles or interest. In addition, separate
models were fitted to the Daegu and Moscow data to verify that
any effect found was coherent between the two sets of data.
The latter approach was deemed most relevant while other
methods were still considered (robust linear models, mixed models)
in our analytical approach.
For each model, results are indicated as the estimate (adjustment
value) for each variable, accompanied by a 95% confidence interval
(CI) and statistical information indicating whether the estimated valueis significantly different from zero. P‐values were not corrected for
multiple testing, as they are only used to identify trends; however,
most observations described below were based on a p‐value threshold
of 0.001 and they were made in two independent datasets (from
Daegu and Moscow); in rare case where an observation was associ-
ated with a different p‐value, it is indicated explicitly.
The data is represented using boxplots (using R default parame-
ters) or histograms.4 | RESULTS
In total, 3683 athletes were tested in Daegu (n = 1808) and/or in Mos-
cow (n = 1875) with at least one observation per athlete for each
event. The age of athletes (mean +/− SD) for Daegu was 26.0 +/−
4.2 years for males and 25.9 +/− 4.4 years for females. In Moscow,
the average age for males was 25.9 +/− 4.3 years and 26.0 +/−
4.3 years for females. Table 1 summarizes the number of athletes
tested for each event depending on their age group, gender, origin
(continents), disciplines, endurance versus non‐endurance disciplines,
and finally the testing period.5 | HEMOGLOBIN OBSERVATIONS
First, box plots in Figure 1A detail the hemoglobin concentrations
(HGB, g/dL) for all factors of interest. Table 2 A1 provides the mean
HGB reference value with the 95% CI, as well as the necessary adjust-
ment coefficients to apply to obtain mean HGB values for all different
classes depicted in Figure 1A. For example, the mean reference HGB
value for male athletes was 15.7 g/dL (15.6–15.8 95% CI). To obtain
the mean value for female athletes, 1.7 g/dL must be deduced from
the reference HGB value (−1.8 to −1.6 with 95% CI). Significant
HGB differences with the reference population were observed. Unsur-
prisingly, gender had a significant impact on HGB. Time of blood col-
lection was also an important confounding factor with a regular
decrease of HGB over the day time. Mean HGB values were signifi-
cantly different (p < 0.01) according to some of the origin of the ath-
letes; for example, athletes from North America and Oceania had
lower mean HGB values compared to the reference population. The
impact of disciplines on HGB values was also of interest, since a signif-
icant adjustment coefficient need to be applied for all of them com-
pared to the reference population (ie, sprint). For some disciplines,
mean HGB were higher (long distance, middle distance, throws) and
for jumps, mean HGB was lower. An important HGB difference was
observed between both events: Mean HGB in Moscow was 0.3 g/dL
lower than in Daegu. An example of how to use the reference tables
is given in Table 3.
The same principle applies to Table 2 A2, but instead of consider-
ing all detailed disciplines, athletes were classified into endurance ver-
sus non‐endurance classes only. The reference population was
included in the non‐endurance class. Figure 2 A1 shows the distribu-
tion of HGB for the reference population with only 40 observations
and no adjustment. To improve the number of observations, the whole
population (3683 observations) was used to set‐up the distribution of
HGB after adjustment (Figure 2 A2). A normal distribution was fitted
TABLE 1 Summary of the total number of athletes tested for each event depending on their age group, gender, origin (continents), disciplines,
endurance versus non‐endurance disciplines, and finally testing period
Age Group
Females
Total
F.
Males
Total
M. TotalDaegu Moscow Daegu Moscow
age < 20 49 34 83 29 40 69 152
20 ≤ age ≤ 30 670 659 1329 793 863 1656 2985
age > 30 129 127 256 138 152 290 546
Total 848 820 1668 960 1055 2015 3683
Continent
Females
Total
F.
Males
Total
M. TotalDaegu Moscow Daegu Moscow
Africa 106 90 196 150 168 318 514
Asia 128 83 211 156 148 304 515
Europe 393 403 796 374 431 805 1601
North America 151 170 321 189 207 396 717
Oceania 31 28 59 49 45 94 153
South America 39 46 85 42 56 98 183
Total 848 820 1668 960 1055 2015 3683
Discipline
Females
Total
F.
Males
Total
M. TotalDaegu Moscow Daegu Moscow
Combined Events 28 32 60 30 34 64 124
Jumps 130 100 230 125 124 249 479
Long Distance 176 205 381 221 292 513 894
Middle Distance 69 71 140 84 85 169 309
Sprint 339 303 642 368 400 768 1410
Throws 106 109 215 132 120 252 467
Total 848 820 1668 960 1055 2015 3683
Endurance
versus non‐
endurance
Females
Total
F.
Males
Total
M. TotalDaegu Moscow Daegu Moscow
Non‐endurance 603 544 1147 655 678 1333 2480
Endurance 245 276 521 305 377 682 1203
Total 848 820 1668 960 1055 2015 3683
Testing period
Females
Total
F.
Males
Total
M. TotalDaegu Moscow Daegu Moscow
7:00 > Test ≤ 11:59 322 285 607 332 374 706 1313
12:00 ≤ Test ≤ 16:59 285 339 624 341 462 803 1427
17:00 ≤ Test < 00:00 241 196 437 287 219 506 943
Total 848 820 1668 960 1055 2015 3683
4 ROBINSON ET AL.to this adjusted data and corresponds to a mean of 15.5 g/dL, with
standard deviation 0.9 g/dL). Some quantiles of the adjusted data
and of the normal distribution fitted to this data were also calculated
and are displayed on the same figure. Some extreme quantiles were
not calculated for the adjusted data, as the number of observations
were too low to obtain meaningful values. The other quantiles are sim-
ilar between the two distributions, indicating that the normal distribu-
tion fits the data very well.6 | RETICULOCYTES OBSERVATIONS
Based on previous publications,21 reticulocyte percentage (%RET)
measurements were transformed using a square root transformation(sqrt%RET). All sqrt%RET are given in detail in Figure 1B. The influ-
ence of all factors is also shown in detail in Table 2 B1 and Table 2
B2. Reticulocytes were significantly higher for female athletes.
Except for Oceanian athletes, the reticulocytes were significantly
lower in the reference population. Combined events, jumps, and long
distance had lower mean reticulocytes than the reference population.
Athletes from the throws' discipline had, in contrast, higher reticulo-
cytes values.
Mean sqrt%RET was 0.03 units higher for Moscow than for
Daegu. Figure 2 B1 shows the distribution of sqrt%RET of the refer-
ence population with no adjustment and Figure 2 B2 the distribution
considering all observations after adjustment. The quantile of the nor-
mal distribution fitted to the adjusted data were calculated for
sqrt%RET. A mean sqrt%RET of 1.00 +/− 0.18 was obtained.
FIGURE 1 Boxplots showing the distributions of hemoglobin levels. A,HGB, g/dL; B, sqrt%RET values (%); C, OFF‐scores; D, ABPS values in each
subgroups taking into account various confounding factors such as gender, age, time of blood collection, origin of athlete, endurance or non‐
endurance disciplines, disciplines, and competitions. The number of athletes in each subgroup is indicated above the graph. The boxes of the
boxplots represent scores between 25% and 75%, with the median indicated with a bold line in the box; outliers are scores >1.5 times the
interquartile range (75%–25%, the length of the box) from the box and are indicated by dots; whiskers extend to the highest or lowest not
considered to be an outlier
ROBINSON ET AL. 57 | OFF‐SCORE OBSERVATIONS
The OFF‐score is calculated as HGB [g/L] – 60*√Ret[%].6,21 Box plots
show the influence of the different factors on OFF‐score values
(Figure 1C). Table 2 C1 and Table 2 C2 give the relevant adjustment
coefficients to apply for each factor of interest. Mean OFF‐score
values were significantly different (p < 0.001) to the reference popu-
lation for gender, time of sample collection, athletes coming from
Asia, North America, and Oceania (p < 0.01 for this last continent).
For some disciplines, the mean OFF‐score values were alsosignificantly different in particular for long distance, throws, and to
some extent middle distance. Furthermore, the event has a signifi-
cant impact on OFF‐score values (higher in Daegu compared to Mos-
cow). OFF‐score distribution with and without adjustment is given in
Figure 2 C1 and Figure 2 C2, respectively. The quantile of the normal
distribution fitted to the adjusted data were calculated for OFF‐
score. A mean OFF‐score of 95.16 +/− 14.17 was obtained. Both fig-
ures confirm that OFF‐score is normally distributed; in particular, the
quantiles obtained for the adjusted data and the normal distribution
are very similar.
TABLE 2 1) List of adjustment coefficients for the different subgroups and different markers, as identified using a linear model, accompanied by
their 95% confidence interval. The “reference” row corresponds to the baseline value for the reference population, as described in the text (male,
between 20 and 30 years old, blood collected in the morning, from Europe, competing in sprint in Daegu); other rows indicate the coefficient,
along with its significance (***: p‐value below 0.001; **: p‐value below 0.01; * p‐value below 0.05; p‐values were not corrected for multiple
testing). Values that were rounded to 0 are indicated with a dash. A1: HGB concentration (g/dL); B1: sqrt%RET levels (%); C1: OFF‐score values;
D1: ABPS values. 2) Similar adjustments as mentioned above except that the “reference” row corresponds to the baseline value for the reference
population, the male, between 20 and 30 years old, blood collected in the morning, from Europe, competing in non‐endurance discipline in Daegu).
A2: HGB concentration (g/dL); B2: sqrt%RET levels (%); C2: OFF‐score values; D2: ABPS values.
A1 A2
Factor 95% CI Factor 95% CI
Reference 15.7 15.6–15.8 Reference 15.6 15.6–15.7
Female −1.7 (***) −1.8 – −1.6 Female −1.7 (***) −1.8 – −1.6
Age < 20 — −0.1 – 0.2 Age < 20 — −0.1 – 0.2
Age > 30 — −0.1 – 0.1 Age > 30 — −0.1 – 0.1
Afternoon −0.3 (***) −0.4 – −0.2 Afternoon −0.3 (***) −0.4 – −0.2
Evening −0.4 (***) −0.5 – −0.3 Evening −0.4 (***) −0.5 – −0.3
Africa 0.1 0–0.2 Africa 0.1 (*) 0–0.2
Asia −0.1 −0.2 – 0 Asia −0.1 −0.2 – 0
North America −0.1 (**) −0.2 – 0 North America −0.1 (**) −0.2 – 0
Oceania −0.2 (**) −0.4 – −0.1 Oceania −0.2 (**) −0.4 – −0.1
South America 0.1 −0.1 – 0.2 South America 0.1 ‐0.1 – 0.2
Combined Events — −0.2 – 0.2 Endurance 0.2 (***) 0.2–0.3
Jumps −0.2 (**) −0.3 – −0.1 Moscow −0.3 (***) −0.4 – −0.3
Long distance 0.2 (***) 0.1–0.3
Middle Distance 0.3 (***) 0.2–0.4
Throws 0.1 (*) 0–0.2
Moscow ‐0.3 (***) −0.4 – −0.3
B1 B2
Factor 95% CI Factor 95% CI
Reference 1 0.98–1.01 Reference 1 0.98–1.01
Female 0.02 (**) 0.01–0.03 Female 0.02 (**) 0.01–0.03
Age < 20 −0.01 −0.04 – 0.02 Age < 20 −0.01 −0.04 – 0.02
Age > 30 −0.01 −0.03 – 0 Age > 30 −0.01 −0.03 – 0.01
Afternoon — −0.02 – 0.01 Afternoon — −0.02 – 0.01
Evening — −0.02 – 0.01 Evening — −0.02 – 0.01
Africa 0.03 (**) 0.01–0.05 Africa 0.03 (**) 0.01–0.05
Asia 0.05 (***) 0.04–0.07 Asia 0.05 (***) 0.03–0.07
North America 0.05 (***) 0.04–0.07 North America 0.05 (***) 0.03–0.07
Oceania 0.01 −0.02 – 0.04 Oceania 0.01 −0.02 – 0.04
South America 0.05 (***) 0.02–0.07 South America 0.05 (***) 0.02–0.07
Combined Events −0.05 (**) −0.08 – −0.02 Endurance −0.03 (***) −0.04 – −0.02
Jumps −0.05 (***) −0.07 – −0.04 Moscow 0.03 (***) 0.02–0.05
Long distance ‐0.04 (***) −0.05 – −0.02
Middle Distance — ‐0.02 – 0.02
Throws 0.07 (***) 0.05–0.09
Moscow 0.03 (***) 0.02–0.05
C1 C2
Factor 95% CI Factor 95% CI
Reference 96.76 95.45–98.07 Reference 96.64 95.46–97.82
Female −18.08 (***) −19.01 – −17.15 Female −18.06 (***) −19 – −17.12
Age < 20 0.75 −1.61 – 3.12 Age < 20 0.82 −1.55 – 3.18
Age > 30 0.71 −0.63 – 2.05 Age > 30 0.47 −0.85 – 1.8
Afternoon −2.83 (***) −3.92 – −1.73 Afternoon −2.85 (***) −3.94 – −1.75
Evening −3.8 (***) −5 – −2.6 Evening −3.85 (***) −5.06 – −2.65
(Continues)
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TABLE 2 (Continued)
A1 A2
Factor 95% CI Factor 95% CI
Africa −0.76 −2.26 – 0.73 Africa −0.73 −2.21 – 0.76
Asia −4.06 (***) −5.51 – −2.6 Asia −4.03 (***) −5.49 – −2.58
North America −4.38 (***) −5.67 – −3.09 North America −4.25 (***) −5.53 – −2.97
Oceania −3.17 (**) −5.58 – −0.76 Oceania −3.26 (**) −5.67 – −0.85
South America −1.88 −4.07 – 0.31 South America −1.86 −4.06 – 0.33
Combined Events 2.8 (*) 0.17–5.44 Endurance 4.14 (***) 3.11–5.17
Jumps 1.62 (*) 0.12–3.11 Moscow −5.2 (***) −6.13 – −4.27
Long distance 4.36 (***) 3.11–5.6
Middle Distance 2.98 (**) 1.2–4.75
Throws −3.01 (***) −4.54 – −1.48
Moscow −5.21 (***) −6.14 – −4.28
D1 D2
Factor 95% CI Factor 95% CI
Reference −0.61 −0.69 – −0.53 Reference −0.62 −0.69 – −0.55
Female −0.7 (***) −0.76 – −0.65 Female −0.71 (***) −0.76 – −0.65
Age < 20 — −0.15 – 0.14 Age < 20 −0.01 −0.15 – 0.14
Age > 30 0.03 −0.05 – 0.11 Age > 30 0.05 −0.03 – 0.13
Afternoon −0.18 (***) −0.25 – −0.12 Afternoon −0.18 (***) −0.25 – −0.11
Evening −0.28 (***) −0.35 – −0.21 Evening −0.28 (***) −0.35 – −0.21
Africa −0.11 (*) −0.21 – −0.02 Africa −0.12 (*) −0.21 – −0.03
Asia −0.04 −0.13 – 0.04 Asia −0.04 −0.13 – 0.05
North America −0.17 (***) −0.24 – −0.09 North America −0.17 (***) −0.25 – −0.09
Oceania ‐0.09 −0.23 – 0.06 Oceania −0.08 −0.22 – 0.07
South America −0.04 −0.18 – 0.09 South America −0.04 −0.17 – 0.09
Combined Events — −0.16 – 0.16 Endurance 0.33 (***) 0.27–0.39
Jumps −0.12 (*) −0.21 – −0.03 Moscow −0.16 (***) −0.22 – −0.1
Long distance 0.35 (***) 0.27–0.42
Middle Distance 0.26 (***) 0.15–0.37
Throws 0.08 −0.01 – 0.18
Moscow −0.16 (***) −0.22 – −0.1
TABLE 3 Example of how to use the reference Table to correct the
HGB concentration (data extracted from Table 2 A1) of a female ath-
lete, tested in Daegu, in the evening, coming from Oceania, and
competing in throws, the reference HGB level
15.7 Baseline for the reference population
‐ 1.7 Adjustment for female athletes
‐ 0.4 Adjustment for testing in the evening
‐ 0.2 Adjustment for an athlete coming from Oceania
+ 0.1 Adjustment for an athlete competing in throws
13.5 HGB baseline for the athlete
ROBINSON ET AL. 78 | ABPS OBSERVATIONS
ABPS box plots are given in Figure 1D considering the various fac-
tors of interest. Table 2 D1 and Table 2 D2 detail the adjustment
coefficient to apply to the mean ABPS value of the referencepopulation for each factor. ABPS distribution with and without
adjustment is given in Figure 2 D1 and Figure 2 D2, respectively,
and quantile of the normal distribution fitted to the adjusted data
were calculated for ABPS. A mean ABPS of −0.67 +/− 0.86 was
obtained; again, the figures show that the normal distribution fit
the data well.9 | OTHER VARIABLES COMMONLY
REPORTED IN A COMPLETE HEMOGRAM
All other blood parameters (RBC, HCT, MCV, MCH, and MCHC) used
for the calculation of ABPS are presented in detail in the Supporting
Information. Additional blood parameters (platelet count: Plt; red
blood cell distribution width: RDW.SD; absolute reticulocyte count:
#RET; immature reticulocyte count: IRF commonly) reported in a usual
hemogram together with serum EPO and ferritin concentrations are
also in the Supporting Information.
FIGURE 2 A, Histograms showing the distribution of the various markers (in our reference population (40 athletes). The values of some quantiles
of interest are indicated above the graph. A1, HGB concentration (g/dL); B1, sqrt%RET levels (%); C1, OFF‐score values; D1, ABPS values.B,
Histogram showing the distribution of the various markers in our complete population (3683 athletes), after adjustment of the levels according to
factors described in the text. The normal distribution fitting the data is plotted in red dashed line over the histogram. Estimated quantiles are
indicated above the plot for both the histogram and the fitted normal distribution. A2, HGB concentration (g/dL); B2, sqrt%RET levels (%); C2,
OFF‐score values; D2, ABPS values.
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All data presented in this article were obtained in an anti‐doping con-
text and not in a medical context. Therefore, the observations pre-
sented here, include also data collected on athletes with various
pathologies such as iron deficiency, malaria, and other possible dis-
eases nevertheless compatible with sport at the highest level of com-
petition. It cannot be excluded that some athletes doped prior to theblood testing; this could have an impact on the blood distribution of
blood values.
It is important to mention that when the Daegu results were
obtained, the effects of some of the confounding factors we consid-
ered on the variability of the blood parameters such as gender, origin
of the athletes, time of collection, and disciplines were more important
than initially expected. This was one of the reasons to conduct once
again such a massive blood testing during a major event. The results
ROBINSON ET AL. 9obtained on the second occasion finally confirmed those obtained dur-
ing the first blood testing.11 | GENERAL CONSIDERATIONS
Hemoglobin is recognized to be a robust variable and easily measured
worldwide, especially when following the same pre‐analytical and ana-
lytical protocols and using the same hematological analyzer, which was
the case in the present study. A recent study demonstrated that
through over 13 000 samples “the current estimate of within‐subject
variance of HGB used by the ABP remains credible.”18 A seasonable
effect has already been observed in several studies with a significant
decrease of HGB during warm months within athletes18,22 and non‐
athlete populations.23 It was notably found out that the decrease of
HGB during the daytime was higher in Daegu than in Moscow, most
likely due to plasma volume changes (data not shown) which might
be explained by the differences in weather conditions, and in accor-
dance with the pre‐cited literature.18,22,23 As previously described,
the reticulocyte percentage has been transformed in square root
values. This transformation has been published elsewhere by Sharpe
et al.6 It is an elegant way to get symmetrical values that are close
to a normal distribution and makes the interpretation of values easier
to observe. On average, during the event in Moscow, the sqrt%RET
was slightly higher (0.03 p < 0.001), but the difference may originate
from multiple sources. Most likely, the difference was due to varia-
tions in calibration of the instruments. Although these differences
were statistically significant, they were analytically not important and
within the acceptance criteria of the normal function. Indeed, having
two analytical sites reporting similar data two years apart is highly
improbable. The setting of the instruments and the standard operating
procedures prevent as much as possible any drift, but the precision of
sqrt%RET to that level still suffers some limitations. On the other
hand, the number of low and very low sqt%RET observed in Daegu
have nearly disappeared for Moscow. For the first time and on such
a large number of athletes, the sqrt%RET distribution curve is given.
This distribution is symmetrical and does not show two separate pop-
ulations. The mean sqrt%RET is close to 1.00 (corresponding to
1.00%RET) with very low or very high values which can be attributed
to pathologies or most probably to doping, as most of the pathologies
are incompatible with sport at the highest level, except maybe a bleed-
ing ulcer which may influence the blood profile and for which the
prevalence is quite high, especially among endurance athletes.2412 | AGE AND GENDER
The mean HGB difference between male and female athletes was
equal to 1.7 g/dL, in line with a previous study which found a differ-
ence of 1.6 g/dL between genders (1376 males and 1073 females18).
While the relation between hemoglobin concentration and aging is
well‐known, with a decrease of 0.06 g/dL per year,25 in this popula-
tion of relatively young athletes (mean age of 26 ± 4 years), age differ-
ence had no significant impact on HGB for male and female athletes.
Studies of this relation are usually made on elder populations and
our results are in line with another study18 where the fixed effect ofage was not significant either in a similar population (ie, elite athletes,
22.3 ± 4.6 years).
The sqrt%RET were significantly higher (p < 0.01) for women
compared to men. Significant differences between male and female
athletes were reported elsewhere26,27 and are similar to our results
and at the same magnitude (ie, higher for women). It has been hypoth-
esized that these differences between genders could be induced by
the estrogen‐dependent production of erythropoietin by the female
reproductive system.28 Thus, it has been suggested that the response
to erythropoietin production and expression of its receptor could be
more pronounced in female athletes.26 Nevertheless, further studies
are needed to better understand the physiological and especially
hematological adaptations of female athletes.13 | ORIGIN OF THE ATHLETES
African and South American male athletes had on average a mean
HGB higher than the reference population whereas the Oceanian ath-
letes had lower HGB values. These observations were not the same
for female athletes, because for both events, mean HGB values were
higher for European athletes than for any other female athlete popu-
lation. Knowing that altitude information could not be taken into
account and considering that male and female athletes most probably
follow the same kind of training camps, it seems that there was a dif-
ference in mean HGB concentration between male athletes from dif-
ferent continents and furthermore, these differences were not the
same for male and female athletes. Therefore, the origin of the ath-
letes does not have a similar impact on male and female athletes (data
not shown).14 | SPORTS DISCIPLINE
In comparison with the reference population (ie, sprint discipline),
mean HGB was higher for long, middle distances, and (to a lesser
extent) throws, and was lower for jumps. Indeed, considering the type
of effort produced by the athletes in the jumps category, ie, very
explosive impulse with only a weak aerobic component, it is logical
to obtain higher HGB concentration in the sprint discipline compared
to jumps. In addition, it is important to keep in mind that the sprint dis-
cipline included distances up to 400 m, during which respectively 29
and 43% of the exercise comes from the aerobic capacity.29 More-
over, in middle and long distances, the aerobic energetic cost rises to
66 and 84% and obviously goes further when the distance is longer
(3000 m, 5000 m, and 10000 m). There were various possible explana-
tions for that; logically, athletes competing in these distance catego-
ries would most likely train at altitude to perform better and
therefore obtain higher HGB values in comparison to the reference.
Objectively, blood doping (ESAs or blood transfusion) could not be
excluded for some athletes. HGB distribution was normal and was
similar to more recently published data.18 On average, and considering
the lack of standardization of pre‐analytical and analytical conditions,
the data reported by Lobigs et al are quite similar to our observations.
On the other hand, HGB patterns vary between different disciplines.
The lack of information regarding testing period during the day time
10 ROBINSON ET AL.and the origin of athletes could eventually explain some of these
differences.15 | OFF‐SCORE AND ABPS
Considering that OFF‐score and ABPS are mathematically calculated
scores based on all parameters previously discussed, their respective
fluctuations are directly induced by the latter. Therefore, a signifi-
cantly lower OFF‐score has been found for women compared to
men induced by a combination of higher sqrt%RET and lower HGB.
ABPS is based on seven hematological variables among which HGB
is also included. Therefore, the behavior of ABPS for each factor is
very like HGB. Under our experimental conditions, both parameters
were highly correlated (data not shown).16 | FURTHER CONSIDERATIONS AND
LIMITATIONS
One of the most important conclusions of this study is certainly that in
the current ABP, the population limits defined for all athletes must be
removed from the system. This population limit is in fact not “fitting
for all,” because of the significant effects of confounding factors
described in this study. The interpretation of the individual ABP can-
not be appropriate when the initial population limits do not consider
the confounding factors the individual may be submitted to. This
makes the work of ABP experts less accurate.
Moreover, it must be assumed that the intra‐individual variability
is not negligible. Therefore, it should be considered to remove the uni-
versal within‐subject variance and replace it by an individual within‐
subject variance which takes better into account important factors in
order to improve the sensitivity of the ABP.
It is also important to keep in mind that the proposed reference
values are adapted to the selected population of this study only, ie,
elite track and field athletes.17 | ALTITUDE
As mentioned earlier, all athletes had to fill in the usual WADA ques-
tionnaire documenting altitude residency, training and competition
(altitude higher than 1500 m) as well as the eventual use of hypoxia
simulation devices (normobaric or hypobaric simulation, intensity and
duration of the exposure to hypoxia) within the two weeks prior to
the blood collection. The level of understanding of some athletes
was limited (questionnaire in English only and not in the mother
tongue of the athlete, lack of education of some athletes) and some
questions were too vague resulting in a poor quality of answers. On
top of that, when double checking the information in the whereabouts
section of ADAMS, it appeared that the information reported in the
questionnaires was not always in agreement with the information
reported in ADAMS. Currently, the information provided by the
WADA questionnaire generates more background than useful and reli-
able information. It cannot be used to finetune the distribution ofblood values among athletes and cannot be used to better understand
atypical blood profiles observed among certain athletes.18 | LIMITATIONS OF THIS STUDY
There are a few limitations to this study. Although some publications
show that plasma volume changes are not that important during the
daytime, this study shows on a large cohort of athletes, that these
changes are significant and should not be ignored. Another limitation
is the quality of the calibration of the instruments; a slight bias could
have a major impact on the distribution of some blood values. It is also
important to add that the blood distributions are valid for track and
field athletes who have been tested following the appropriate operat-
ing WADA guidelines or technical documents. Any deviation could
have a significant impact on blood data.19 | CONCLUSION
With newer guidelines for blood collection and analyses, our study
gathered blood samples of all athletes competing in two major events
in 2011 and 2013 to define solid reference values. New reference
values for elite track and field athletes are thus proposed here with
considerations of the actual ABP guidelines and several factors alter-
ing ABP data. Our findings reveal that selected factors (ie, gender, ori-
gin, time of collection, discipline) have a significant influence on
several hematological parameters involved in the ABP. In addition, sig-
nificant differences were observed between both events which may
highlight a climatic influence (eg, ambient temperature, humidity) on
hematological parameters. This new reference dataset can be used
to better select reference populations and set individual references
for the current ABP. Furthermore, these data will be used in the future
to determine more precisely which sub‐population of athletes (classifi-
cation done by age group, sport, discipline, sport's nationality, event)
were likely doping (blood doping with ESA and/or transfusion).30ACKNOWLEDGEMENTS
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